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Photodynamic therapy (PDT) of cancer involves the systemic
administration of a photoactive molecule known as a photosensi-
tizer (PS), followed by illumination of the specified tissue volume
with activating light of the correct wavelength to excite the PS,
which in the presence of oxygen forms cytotoxic oxygen species
that destroy the tumour (Hasan and Parrish, 1996). This tumour
destruction can be due to direct cytotoxic effects on the tumour
cells themselves, or to the destruction of the tumour blood supply
due to constriction and stasis produced in the tumour vasculature
depending primarily on whether the PS is located in the tumour
interstitium or in the tumour vasculature (or for very early illumi-
nation times, in the blood) (Henderson and Dougherty, 1992). For
commonly used PS, the relative amounts in the vasculature and the
interstitium are governed by the time after administration at which
illumination is performed (Boyle and Dolphin, 1996). These two
mechanisms of tumour destruction can have different therapeutic
effects on various sizes and types of tumours (Henderson et al,
1997). In addition to cancer, there is a growing number of applica-
tions of PDT to diseases where neovasculature needs to be
destroyed, e.g. age-related macular degeneration (Schmidt-Erfurth
et al, 1994), psoriasis (Calzavara-Pinton et al, 1996) and angiomas
(Orenstein et al, 1990). An understanding of the factors governing
the partitioning of the PS between blood vessels and tissue will
broaden the potential applications of PDT and allow the rational
design of PDT protocols. The ideal method of gaining information
on this partitioning behaviour would be non-destructive and
provide kinetic data in real time.
Although the tetrapyrrole compounds commonly used as PS
have some selectivity for tumours (Hamblin and Newman, 1994a),
means are being sought to increase this selectivity by using conju-
gates between PS and macromolecular carriers with targeting
properties (Hasan, 1992). These targeting species include mono-
clonal antibodies (Duska et al, 1997), lipoproteins (Hamblin and
Newman, 1994b), microspheres (Bachor et al, 1991), liposomes
(Cuomo et al, 1990) and polymers (Krinick et al, 1994). The latter
may be either natural polymers such as dextran (Rakestraw et al,
1990) and polyamino-acids (Goff et al, 1991; Soukos et al, 1997)
or synthetic polymers such as N-(2-hydroxypropyl)-methacryl-
amide (Seymour et al, 1987) and polyvinyl alcohol (Davis et al,
1993). Polymer–drug conjugates have been proposed as targeting
vehicles for delivery of cytotoxic drugs to tumours (Kopecek,
1991; Duncan and Spreafico, 1994). Advantages claimed include
decreased systemic toxicity (Zunino et al, 1987; Yeung et al,
1991), and selective accumulation in tumours due to the phenom-
enon known as enhanced permeability and retention (Dvorak,
1986; Seymour, 1992). The increased permeability of tumour
blood vessels is also responsible for the initial selective tumour-
localizing ability of many macromolecules, such as Evans blue-
albumin (Matsumura and Maeda, 1986), monoclonal antibodies
(Dvorak et al, 1991), lipoproteins (Leppala et al, 1995) and small
liposomes (Yuan et al, 1994). Enhanced retention of polymeric
drugs is thought primarily to be due to the absence of an adequate
system of lymphatic vessels (which would remove non-bound
macromolecules) in solid tumours (Butler et al, 1975). The selec-
tive retention of other targeting species such as drugs bound to
monoclonal antibodies (Mariani et al, 1995) or lipoproteins
(Masquelier et al, 1986) has an additional component due to
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Summary Polymeric drug conjugates are used in cancer therapy and, varying their molecular size and charge, will affect their in vivo
transport and extravasation in tumours. Partitioning between tumour vasculature and tumour tissue will be of particular significance in the
case of photosensitizer conjugates used in photodynamic therapy, where this partitioning can lead to different therapeutic effects. Poly-l-lysine
chlorin e6 conjugates (derived from polymers of average Mr 5000 and 25 000) were prepared both in a cationic state and by poly-succinylation
in an anionic state. A fluorescence scanning laser microscope was used to follow the pharmacokinetics of these conjugates in vivo in an
orthotopic rat prostate cancer model obtained with MatLyLu cells. Fluorescence was excited with the 454–528 nm group of lines of an argon
laser and a 570 nm long pass filter used to isolate the emission. Results showed that the conjugates initially bound to the walls of the
vasculature, before extravasating into the tissue, and eventually increasing in fluorescence. The anionic conjugates produced tissue
fluorescence faster than the cationic ones, and surprisingly, the larger Mr conjugates produced tissue fluorescence faster than the smaller
ones with the same charge. These results are consistent with differences in aggregation state between conjugates.
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The preparation of conjugates between tetrapyrrole PS and
polymers poses special challenges. They may aggregate to a
greater or lesser extent due to the amphiphilic nature of
hydrophobic tetrapyrroles joined to hydrophilic polymer chains.
Water-soluble PS–polymer conjugates must be relatively
hydrophilic, but may bear net cationic, anionic or neutral charges
(Soukos et al, 1997). They may also be prepared with varying size
distributions according to the molecular weight range of the
original polymer. Varying the net charge and the molecular weight
range of the conjugates may be expected to have profound effects
on the kinetics of transport of PS out of the bloodstream and into
the tumour. These questions are difficult to answer in vivo, and are
the subject of the present study.
Because all PS are to a greater or lesser degree fluorescent, in
vivo fluorescence microscopy is an attractive non-destructive
method for obtaining pharmacokinetic information on the trans-
port and distribution of PS in real time. This report describes the
first use of in vivo laser scanning fluorescence microscopy to
follow the transport of macromolecular–PS conjugates in vivo,
and the first use in an orthotopic tumour model. These conjugates
between chlorin e6 (ce6) and poly-l-lysine (pl) had two sizes,
being derived from pl chains of average Mr 5000 and 25 000 and
referred to hereafter as ‘small’ and ‘large’, and also had opposite
charges, unmodified, referred to as ‘cationic’, and succinylated,
referred to as ‘anionic’. An orthotopic rat prostate cancer model
derived from MatLyLu cells (Vieweg et al, 1994) was selected
because this model is metastatic in advanced stages, and allows the
testing of treatments for effects on both local control and distant
metastasis. In addition, the tumour was amenable to in vivo
fluorescence microscopy presenting a 1–2 cm relatively flat-
topped tumour for imaging. There is also evidence that orthotopic
animal tumours may have vasculature that is more representative
of that found in human tumours than subcutaneous implanted
tumours (Fukumura et al, 1997).
MATERIALS AND METHODS
Cells
R-3327 MatLyLu (a cell line derived from the Dunning rat prostate
cancer) was a generous gift from Dr WD Heston (Urologic
Oncology Research Laboratory, Memorial Sloan-Kettering Cancer
Center, New York, NY, USA). It was grown in RPMI-1640 with L-
glutamine (Mediatech, Washington, DC, USA) supplemented with
10% fetal bovine serum (FCS) (Gibco, Grand Island, NY, USA),
penicillin (100 units ml–1) (Sigma, St Louis, MO, USA) and
streptomycin (100 mg ml–1) (Sigma). Cells were grown at 37°C in
an atmosphere of 5% carbon dioxide and were passaged every 4–5
days. The continuous human endothelial hybrid cell line EA.hy926
(Edgell et al, 1983) was a generous gift of Dr C-JS Edgell
(Department of Pathology, University of North Carolina, Chapel
Hill, NC, USA). Cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) with high glucose (Gibco) supplemented with
heat-inactivated 10% FCS, penicillin, streptomycin and in the pres-
ence of HAT (100 mM hypoxanthine, 0.4 mM aminopterin, 16 mM
thymidine (Gibco)). Medium was changed twice a week. Cells
were subcultured weekly using trypsin–EDTA (Gibco) at a relative
cell density of 1:16.
Animal model
All animal procedures were approved by the Institutional
Subcommittee on Research for Animal Care and were in compli-
ance with the UKCCCR Guidelines (UKCCCR, 1998). There was
no suffering or undue interference with the normal lifestyle of the
rats. Experiments were carried out on male Copenhagen rats
(2 months) (Harlan Sprague Dawley, Indianapolis, IN, USA). Rats
were anaesthetized with ketamine cocktail (ketamine, xylazine
and atropine) after slow induction with Metophane (methoxy-
flurane; Pitman-Moore, Washington Crossing, NJ, USA). After
anaesthesia, a 2-cm longitudinal incision was made in a cranial
direction starting from above the pubic bone, and the ventral lobe
of the prostate was exposed by retracting the bladder. Then, 104
MatLyLu cells in 0.1 ml of phosphate-buffered saline (PBS) were
injected into the ventral lobe of the prostate. To prevent any spilled
tumour cells from growing outside the prostate a few drops of
povidone iodine solution 10% USP (Clinipad Corp., Guilford, CT,
USA) was instilled in the injection site. The abdomen was closed
with 2–0 silk. Three weeks after tumour cell injection almost
spherical tumours had grown to 1–2 cm diameter (less than 5%
body weight), completely replacing all normal prostate tissue in
the ventral lobe, and substantial amounts of normal prostate in the
dorsal lobe.
Preparation and characterization of conjugates
The preparation of the conjugates has been described previously
(Soukos et al, 1997). Briefly, poly-l-lysine HBr (polypeptide
average Mr 25 000, degree of polymerization (DP) = 196 or
average Mr 5000, DP = 40) was reacted with ce6-N-hydroxy-
succinimide ester in dry dimethyl sulphoxide (DMSO) and either
purified by extensive dialysis or further reacted with an excess of
succinic anhydride before purification. The degree of ce6 substitu-
tion on the polylysine chains was estimated by measuring the
absorbance at 400 nm and calculating the amount of ce6 present
using e400 nm = 150 000 l mol–1 cm–1. The amount of polylysine was
assumed to be the original quantity weighed out. After exhaustive
dialysis it was assumed that the remaining ce6 was covalently
bound to the pl. Free ce6 was dissolved in 0.1 M aqueous sodium
hydroxide (NaOH), diluted in PBS and neutralized with 0.1 M
hydrochloric acid.
In vitro
MatLyLu or EA.hy926 cells were trypsinized in the exponential
growth phase and counted using a haemocytometer. Then, 105
cells in 1 ml growth medium with 10% FCS were seeded into each
well of 24-well culture plates. These were returned to the incu-
bator and kept at 37°C for 24 h to allow cells to attach and resume
exponential growth, medium was removed and replaced with
growth medium with 10% FCS containing conjugates or free ce6
at a concentration of 0.4 mM ce6 eq in triplicate wells, and again
kept at 37°C. At all times the plates were protected from light by
wrapping in aluminium foil. After 6 h had elapsed, the drug
solution was aspirated from the wells, the cells were washed
three times with 1 ml sterile PBS and incubated with 1 ml
trypsin–EDTA for 10 min. The resulting cell suspension was then
centrifuged, the trypsin supernatant was aspirated and retained,
and the pellets (visibly fluorescent under long-wave UV) were
dissolved in 1.5 ml 0.1 M NaOH per 1% sodium dodecyl sulphate
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ment has been shown not to alter the fluorescence of the conju-
gates. The fluorescence of the cell extract was measured on a
spectrofluorimeter (model FluoroMax, SPEX Industries, Edison,
NJ, USA) and all measurements were made at concentrations at
which the fluorescence versus concentration curve was linear. The
excitation wavelength was 400 nm and the emission spectra of the
cell suspensions were recorded from 580 to 700 nm. The fluores-
cence values were converted into mol equivalents of ce6 by
comparison with a calibration curve constructed with known
amounts of each of the conjugates. The protein content of the
entire cell extract was then determined by a modified Lowry
(Larson et al, 1986) method using bovine serum albumin dissolved
in 0.1 M NaOH per 1% SDS to construct calibration curves. The
trypsin supernatant was also checked for the presence of fluores-
cence, which was negligible. Results were expressed as nmol of
ce6 per mg cell protein.
Aggregation studies in serum
Sufficient conjugate was added to 2 aliquots of 1.5 ml pure horse
serum (Gibco) to give a ce6 eq concentration of 20 mM. Then,
750 ml of each aliquot were then serially diluted with 750 ml of
horse serum 11 times to give two identical series of twofold serial
dilutions from 20 mM to 10 nM. One set of dilutions was then
centrifuged at 16 000 g for 15 min at 4°C while the other set was
gently agitated. Three aliquots were taken from the supernatant of
the centrifuged tubes and from the agitated tubes and each aliquot
added to 1.4 ml 0.1 M NaOH per 1% SDS and the fluorescence
measured as previously described. The fraction aggregated was
calculated from the difference between the fluorescence in the
supernatant of the centrifuged samples, and that in the agitated
samples.
Laser scanning fluorescence microscope
The laboratory prototype scanning laser microscope (SLM) was
developed for video-rate (30 frames per second) fluorescence
imaging of tumours and vasculature in vivo. The SLM is a modi-
fied version of a video-rate confocal scanning laser microscope
that was originally built for reflectance imaging of tissue in vivo.
By using a low numerical aperture objective lens and large
detector aperture, we could image in a non-confocal mode.
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Figure 1 Schematic of the in vivo imaging system for orthotopic rat prostate
tumours
Figure 2 Structure of the cationic and anionic conjugatesDetails of the optical design have previously been published
(Rajadhyaksha et al, 1995). Illumination was obtained by coupling
an argon-ion laser (Innova 100, Coherent, Palo Alto, CA, USA),
into the SLM. Video-rate horizontal and vertical scanning was
with a rotating polygon mirror (model M225030XLIM with
controller VFC2, Lincoln Laser, Phoenix, AZ, USA) and an oscil-
lating galvanometric mirror (model G325DT, General Scanning,
Watertown, MA, USA) respectively. The intermediate optics in the
scan system consisted of folding mirrors and achromatic lenses.
The detector was a silicon avalanche photodiode (model
C39050E, EG&G Optoelectronics, Quebec, Canada). The detector
output was sent to a video monitor and video storage devices such
as a S-VHS videotape recorder (Panasonic AG-7300) and an eight
bits per pixel frame grabber (model Pixelpipeline PTP425,
Perceptics, Knoxville, TN, USA).
We used a 2.53, 0.07 numerical aperture objective and a
detector aperture of 1 mm diameter (i.e. 600 mm at the tissue.) The
imaging was with 30 mW of argon-ion 454–528 nm multilines,
and with a 570 nm long pass filter which transmitted only the
fluorescent image to the detector. The images were ‘grabbed’ with
the frame grabber, each grabbed image being an integration of four
frames. Four frames is the optimum compromise between
increasing the image signal-to-noise ratio and introducing blurring
caused by animal motion. The frame-grabber gain was typically
200 and offset was 100 for grabbing the images. With the 2.53,
0.07 numerical aperture lens, we measured a spot of diameter of
10 mm at the tissue. When the laser beam scans the field of view,
each spot on the tissue is illuminated with 30 mW for approxi-
mately 400 ns. Thus each spot receives 0.02 J cm–2 of energy, and
grabbing each image required approximately 5 s. If we assume
continuous illumination during this time over the field of view of
6.4 ´ 3.4 mm, the energy deposited on the tissue is 0.7 J cm–2 for
each image.
In vivo fluorescence microscopy
Rats were anaesthetized as described above, and a 3 cm longitu-
dinal incision was made in a cranial direction from the top of the
symphysis pubica, which was sufficient to completely expose the
tumour-bearing prostate. The skin of the abdominal incision was
sutured with 1–0 silk to the skin of the inside of the thigh in order
to permanently retract the incision for the duration of the experi-
ment. A 5 cm square of surgical gauze was soaked in saline, rolled
up and inserted into the upper abdomen to retain the intestines in
place out of the observation field. Figure 1 shows a schematic
representation of the imaging setup.
The conjugates or free ce6 (250 mg ce6 eq per 250 g rat) were
dissolved in 1 ml of PBS and slowly injected (over at least 5 min)
via the penile vein. Images were captured as described above, and
rats were kept warm in between imaging. When rats showed any
sign of regaining consciousness they received additional anaes-
thesia via inhalational metophane. At the completion of the exper-
iment, rats were sacrificed with a large overdose of intravenous
ketamine. At least three rats were imaged for each of five
compounds. Imaging usually continued for as long as the fluores-
cence levels in the images continued to increase. This time varied
from 90 min to 8 h.
Image processing
Images were captured with comparable levels of argon-laser
power and gain settings so the grey scale levels in subsequent
images were directly comparable. Since it was apparent that the
levels of fluorescence observed in any single tumour were some-
what inhomogenous, at least two areas were chosen for imaging in
each tumour. Due to the necessity of having a relatively level
tumour surface for imaging it was seldom possible to have more
than three observation fields in any single tumour without signifi-
cant overlap. Images were divided into three compartments, blood
vessel interior, blood vessel wall and tumour tissue. For each
image the grey scale values of each compartment were measured
by averaging the values of at least 100 pixels in each compartment
including the most and least fluorescent pixels. Means and
standard errors were then generated from the 100-pixel values
from images from each of three rats at each time point.
RESULTS
Preparation of conjugates
The large polylysine chain (average Mr 25 000, DP = 196), was
found to have an average of 20 ce6 molecules attached per chain
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Table 1 In vitro uptakes of the conjugates by prostate cancer cells and
endothelial cells
Conjugate MatLyLu cells Ea.hy926 cells
Free ce6 0.005 ± 0.001 0.0015 ± 0.0003
Large anionic 0.2 ± 0.045 0.056 ± 0.004
Small anionic 0.26 ± 0.02 0.11 ± 0.022
Large cationic 1.93 ± 0.327 1.15 ± 0.216
Small cationic 3.3 ± 0.31 2.2 ± 0.314
Large (ratio: cationic/anionic) 9.65 ± 1.95 20.53 ± 4.25
Small (ratio: cationic/anionic) 12.7 ± 2.3 20.27 ± 3.7
Cells were incubated with conjugates at 1 mM ce6 eq concentration in serum
containing medium for 6 h at 37°C. Trypsinized cells were extracted and ce6
quantified by fluorescence spectroscopy and cell protein measured by a
modified Lowry procedure. Results are expressed as nmol ce6 eq per mg cell
protein. Values are means of two experiments each containing 3 wells and
errors are s.e.m.
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Figure 3 Aggregation of the conjugates in serum. Values show the fraction
of ce6 eq which was pelleted after centrifugation at 16 000 g for 15 min at
4°C as a function of ce6 concentration in 100% horse serum. The fraction
aggregated was calculated from the difference between the fluorescence in
the supernatant of the centrifuged and that in the agitated samplesthus raising the average Mr to approximately 37 000 for the large
cationic species, and after succinylation to approximately 54 500
for the large anionic species assuming complete succinylation. The
small polylysine chain (average Mr 5000, DP = 40) had an average
of 7 ce6 molecules attached per chain, thus giving Mr values of
approximately 9000 and 12 000 for the small cationic and small
anionic species respectively. The structures are shown in Figure 2.
In vitro uptake of conjugates
Uptake experiments were performed to investigate if there
were any differences in the interaction of the conjugates with
endothelial cells and prostate cancer cells which could account for
observed differences in the pharmacokinetics in vivo. The results
(Table 1) showed that the uptake of ce6 by both cell lines was
many times higher for the cationic conjugates than the anionic
conjugates, which in turn had much higher uptake than free ce6.
Both cell lines took up significantly more ce6 from the small
cationic conjugate than the large, while the difference in uptake
between the large and small anionic conjugate was less
pronounced. The prostate cancer cells in every case took up more
ce6 than the endothelial cells, but when the ratio of uptake from
the cationic to anionic conjugates was examined (Table 1) it can be
seen that in fact the endothelial cells had a greater preference for
the cationic conjugate of both sizes than the prostate cancer cells.
Aggregation in serum
In order to gain some insight into the behaviour of these conjugates
in the bloodstream, we carried out a series of experiments to
investigate their aggregation behaviour in 100% horse serum. All
the conjugates are highly aggregated in PBS but it was visually
apparent that there were differences between the conjugates in
serum. Since the aggregates formed by the small conjugates were
sufficiently large to fall out of solution, we compared their behav-
iour after centrifugation with that after gentle agitation. The results
are shown in Figure 3. It can be seen that there is a very significant
difference between the large and small conjugates of both charges.
The large conjugates are almost completely disaggregated in
serum, while the small conjugates are between 40 and 60% aggre-
gated. There is a difference in the extent of aggregation between the
small cationic and small anionic conjugates at the higher concentra-
tions. It should be noted that assuming the plasma volume of
a 250 g rat is 10 ml, then the initial concentration of ce6 eq after
injection of 1 mg kg–1 body weight is approximately 40 mM.
Intratumoural transport and pharmacokinetics by
fluorescence imaging
Examples of images captured from the fluorescence imaging
studies are shown in Figure 4 A–H. The initial images (Figure 4
A,C,E,G) were usually less fluorescent but in better focus than the
intermediate images, while the focus improved towards the end of
the imaging (Figure 4 B,D,F,H) when the vasculature became
negative with respect to the rest of the tissue. Considerable hetero-
geneity was observed in the degree to which different types of
tumour vasculature extravasated fluorescence. Areas where the
blood vessels were convoluted were especially ‘leaky’ (Figure 4
A,B), while large straight vessels were less leaky and small
straight vessels the least. Fluorescence can be seen on the vessel
wall in Figure 4 E,G. With some conjugates there was a significant
‘lag’ period after the fluorescence had leaked out into the tissue,
and the blood vessels had become negative, before the fluores-
cence intensity in the tissue rose dramatically.
The fluorescence imaging technique allows the preparation of
relative pharmacokinetic curves for three separate compartments
of the tumour; the interior of the blood vessels, the walls of the
blood vessels and the tumour interstitium. The curves for the
increase in fluorescence in the tissue compartment from the four
conjugates and free chlorin e6 is shown in Figure 5. The fluores-
cence in the blood vessel interior reached a peak shortly after
injection (2–10 min) and reduced fairly rapidly, dropping to a low
value in every case by 50–100 min after injection. At some time
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Figure 4 Pairs of images from laser scanning fluorescence microscopy, one
at an early time point and one at a late time point. Arrows indicate landmarks
for orientation in pairs of images. The grey scale values of these images
have been optimized for brightness and contrast for printing, and are only
proportional to the grey scale values which were used for calculation of
pharmacokinetics. (A, B) Free ce6; (C, D) Small anionic; (E, F) Large
cationic; (G, H) Small cationic. Scale bar is 500 mm in every caseafter injection the fluorescence could be observed to localize on
the walls of the blood vessels, and the peak of this localization
occurred between 20 and 40 min after injection, depending on the
conjugate injected. The peak intensity of the vessel wall fluores-
cence was always higher than the peak observed in the interior of
the blood vessels. The vessel wall fluorescence remained strong
only for a period of 30–50 min before disappearing. The fluores-
cence in the tissue between the blood vessels increased at distinct
rates for each injected species (Figure 5). The relative rates of
increase of tissue fluorescence could be illustrated by the times
required for the fluorescence to reach a mean graey scale level of
100 in the tissue and were as follows: free ce6 (20 min) > large
anionic (63 min) > small anionic (107 min) > large cationic
(202 min) > small cationic (307 min).
DISCUSSION
The rate and extent to which intravenously injected PS partition
from the vasculature into tumour tissue can have important impli-
cations for the optimum time for light delivery in PDT. This study
has shown that there are dramatic and surprising effects of both
size and charge of the polymer–PS conjugates on the pharmaco-
kinetics of fluorescence distribution between vasculature and
interstitium in an orthotopic rat prostate tumour model. This was
feasible because in vivo laser scanning fluorescence microscopy
provides a non-destructive method of gaining pharmacokinetic
information in real time.
In vitro studies showed that, although the prostate tumour cells
took up more of the conjugates of both sizes and charges than the
endothelial cells, in fact the ratios of the uptakes of the cationic to
anionic was higher for the endothelial cells than the prostate
cancer cells. This implies that, although both cell types are nega-
tively charged, the endothelial cells have a relatively higher nega-
tive charge than the prostate cells, while the latter have a greater
capacity for endocytosis. This higher binding of the cationic
conjugates to endothelial cells is in agreement with literature
reports that endothelial cells express anionic regions on the glyco-
calyx (Haldenby et al, 1994), fenestral membranes (Ghinea and
Simionescu, 1985) and vesicular openings (Baldwin and Chien,
1984), all of which have a pronounced tendency to bind polyca-
tions. These anionic regions are thought to play a role in modi-
fying permeability and transcytosis of macromolecules
(Simionescu and Simionescu, 1986). The reason for the differ-
ences in cellular uptake between the small and large conjugates of
the same charge was less clear. The most likely explanation is
provided by the observed difference in the degree of aggregation
between the small and large conjugates of both charges. The
aggregation behaviour of these conjugates is complicated and
highly dependent on solvent (MR Hamblin and T Hasan, unpub-
lished results); however, in 100% serum the small conjugates are
significantly more aggregated than the larger ones (Figure 4),
which may explain their higher cellular uptake. Aggregates may
bind strongly to the plasma membrane or be internalized by
phagocytosis. An alternative explanation is that the increased
uptake of the small cationic compared to the large cationic is due
to more pronounced endocytosis of smaller molecules. The
extremely low cellular uptake of free ce6 compared to that
observed from the conjugates is in agreement with previous
reports with similar conjugates (Soukos et al, 1997). Considering
these in vitro results, we predicted that the cationic conjugates
when injected in vivo, should bind to the endothelial cells in the
tumour blood vessels, while the anionic conjugates should bind
less to the endothelium, and therefore should be able to pass
through the walls of the vessel faster. We supposed that the small
conjugates would extravasate faster than the large ones of the same
charge, as suggested by several previous studies on the molecular
size dependence of extravasation (Mayhan and Heistad, 1985; Ley
and Arfors, 1986; Yuan et al, 1995).
There are differences of opinion as to the extent to which in vivo
measurements of fluorescence can be correlated with the concen-
tration of fluorophore in tissue (Bernstein et al, 1991; Frisoli et al,
1993), and to what extent it can be correlated with photodynamic
efficacy (van Leengoed et al, 1994). The attenuation of fluores-
cence in tissue can be due to absorption and/or scattering of both
excitation and emission light. It is clear that this applies to some
extent to the blood vessels in the present study. At early time
points, when the majority of fluorescence is still in the vessel
interior or vessel wall, the total intensity of fluorescence is signifi-
cantly less than at later time points. The marked increase of tissue
fluorescence occurring some time after the fluorescence appeared
to have ceased moving through the blood vessel walls may be due
either to an increase in the fluorescence quantum yield, or to a
lessening in the extent to which the fluorescence is reduced due to
absorption and scattering. In the former case, the fluorescence
quantum yield could increase because the polymeric conjugates
have been metabolized by, for example, lysosomal proteases
(Krinick et al, 1994), to free ce6 which has a greater fluorescence
quantum yield (data not shown), or because the conjugates under-
went a disaggregation process, similar to that which has been
reported to occur with Photofrin® (Bottiroli et al, 1990). In the
latter case, the increased distance of the fluorophore from the
blood vessels could have reduced the scattering of excitation or
emission light by erythrocytes, or absorption of excitation or emis-
sion light by haemoglobin.
Although there is broad agreement on the fact that certain types
of tumour vasculature have dramatically increased permeability to
macromolecules (Dvorak et al, 1988; Yuan et al, 1994), and that
this is the result of tumour-secreted angiogenesis factors such as
vascular endothelial growth factor (Senger et al, 1993), the precise
mechanism of the hyperpermeability is not certain (Hobbs et al,
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Figure 5 Time-dependent increase of fluorescence in the tumour
interstitium. The grey scale levels of at least 100 pixels in the tissue
compartment were averaged for each image, values are the means of these
mean values for three rats at each time point, and bars are s.e.m.1998). Transport of molecules out of tumour blood vessels can be
a combination of a paracellular process (Jain, 1987), when it is due
to discontinuous endothelium (Jain, 1988), wide inter-endothelial
cell junctions (Jain, 1989) and fenestrations (Roberts and Palade,
1995), and a transcellular process (Kohn et al, 1992) when it is due
to increased expression and function of a system of vesiculo-
vacuolar organelles which transport macromolecules from the
apical to the basal membrane (Dvorak et al, 1996). The mechanism
operating may have implications on the charge selectivity of
transendothelial transport. It has been shown that membrane of
the vesicular–vacuolar neck has no strongly anionic residues
(Simionescu et al, 1981), thus allowing negatively charged macro-
molecules to penetrate into the vesicle, while cationic macromole-
cules remain bound to other regions of the luminal endothelial
surface (Ghinea and Simionescu, 1985). This would explain the
faster extravasation of the anionic conjugates compared to the
cationic ones.
All reports (Ley and Arfors, 1986) that have investigated the
size dependence of the rate of extravasation of macromolecules
both in tumour (Yuan et al, 1995) and normal vasculature (Mayhan
and Heistad, 1985), have concluded that small molecules come out
of the blood vessels faster than large ones, and the Stokes–Einstein
radius is thought to be a good predictor of extravasation of neutral
macromolecules (Nugent and Jain, 1984; Ojteg et al, 1987).
(However, there have been no reports on the size dependence of
rates of extravasation of molecules that contain tetrapyrrole struc-
tures with their innate tendency to aggregate.) Considering these
reports we were very surprised to find that the large conjugates of
both charges gave faster fluorescence increase than the equiva-
lently charged small conjugates. One explanation of this observa-
tion is that the small conjugates in fact behave as if they were
larger than the large ones, and corroboration of this hypothesis is
gained from the aggregation experiments in 100% serum, where
the large conjugates were completely disaggregated, while the
small ones remained more than 40–60% aggregated. Presumably
this disaggregation is an equilibrium process as, in vivo, all the
fluorescence eventually came out of the blood vessels, the small
conjugates just taking considerably longer than their large
analogues. Other explanations could include differences in spatial
conformations and modes of folding of the larger conjugates
compared to the smaller, which could lead to shielding of charges
or alteration of hydrophobic interactions.
In summary, we have shown that the use of the in vivo laser
scanning fluorescence microscope can give real-time information
on the rate of extravasation of PS and PS conjugates. The knowl-
edge of the rate of extravasation of PS of varying structures, and
their distribution between the vascular and parenchymal compart-
ments of the tumour could have implications for the timing of light
delivery in PDT. Previous reports have deduced this rate and parti-
tioning indirectly by measuring serum half-lives (Bellnier et al,
1993) and by characterizing photodynamic tissue damage as
predominantly mediated by vascular effects or by tumour cell
damage (Henderson et al, 1997). Applications utilizing the PDT-
mediated destruction of unwanted neo-vasculature, such as in age-
related macular degeneration (Schmidt-Erfurth et al, 1994),
require that the PS be localized in or near the blood vessels.
Conversely, it has been suggested that to gain the best tumouricidal
effect from PDT it is necessary to have a combination of vascular
effects and direct tumour cell killing effects (Henderson et al,
1997). The next step in this study is to measure actual tissue
concentrations of ce6 and then to treat tumours in this animal
model with these conjugates, and correlate the physiological
response with the time of light delivery and the precise structure of
the conjugate injected.
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